Stephens Investment Management Group LLC Has $57.37 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Stephens Investment Management Group LLC grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 102,097 shares of the company’s stock after buying an additional 4,715 shares during the period. Stephens Investment Management Group LLC owned approximately 0.13% of IDEXX Laboratories worth $57,367,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of IDXX. SHP Wealth Management acquired a new position in shares of IDEXX Laboratories in the fourth quarter valued at about $26,000. Virtus Advisers LLC acquired a new stake in IDEXX Laboratories in the 3rd quarter worth about $26,000. Park Place Capital Corp acquired a new stake in IDEXX Laboratories in the 4th quarter worth about $29,000. WealthCollab LLC bought a new stake in IDEXX Laboratories in the 2nd quarter valued at about $30,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in IDEXX Laboratories in the 3rd quarter valued at about $36,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

IDXX has been the topic of several recent research reports. Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 25th. UBS Group reduced their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Citigroup started coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Finally, Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $557.80 on Friday. The firm has a 50 day moving average of $555.31 and a 200-day moving average of $609.16. The stock has a market capitalization of $44.00 billion, a PE ratio of 41.08, a PEG ratio of 3.05 and a beta of 1.55. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12 month low of $506.91 and a 12 month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities research analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.